Advancing Discovery Summit Series

On March 21–22, 2018 NAMI, the Stanley Center for Psychiatric Research at Broad Institute and the Psychiatric Genomics Consortium hosted the third in a series of Advancing Discovery Summits in Cambridge, Massachusetts. The two-day, invitation-only event convened a diverse group of neuroscience thought leaders from academia and industry, advocacy, government and public policy.

The Advancing Discovery Summit series is a concentrated effort to bring stakeholders from many sectors together to address a very challenging issue. Many medications for mental illnesses have significant side effects ranging from weight gain to movement disorders like tardive dyskinesia—but very few new medications are being developed. NAMI strives to empower our members to advocate for more funding and support for the scientific research that will lead to better therapies. With our partners in brain research, genetic research, pharmaceutical development, and policy—and with your support—we can advance this goal.

Readings and Resources


Working Together to Advance Discovery and Reignite Hope – a white paper co-authored by NAMI's Dr. Ken Duckworth, Dr. Teri Brister and Elizabeth Stafford, along with the Broad Institute's Dr. Rosy Hosking placing the Advancing Discovery Summit's exciting work in an important historical context. 

Time for New Schizophrenia Rx – a compelling editorial from Dr. Steve Hyman, Director of the Stanley Center for Psychiatric Research, which provided the initial motivation for the Advancing Discovery Summit.

Advancing Discovery Summit 2018 Summary Report – a thorough overview of the meeting's objectives and proceedings.

Advancing Discovery Summit 2017 Summary Report – a thorough overview of the meeting's objectives and proceedings.